[go: up one dir, main page]

RU2016118775A - Prionic Acid Controlled Release Pharmaceutical Composition - Google Patents

Prionic Acid Controlled Release Pharmaceutical Composition Download PDF

Info

Publication number
RU2016118775A
RU2016118775A RU2016118775A RU2016118775A RU2016118775A RU 2016118775 A RU2016118775 A RU 2016118775A RU 2016118775 A RU2016118775 A RU 2016118775A RU 2016118775 A RU2016118775 A RU 2016118775A RU 2016118775 A RU2016118775 A RU 2016118775A
Authority
RU
Russia
Prior art keywords
pharmaceutical composition
controlled release
wax
cellulose
composition according
Prior art date
Application number
RU2016118775A
Other languages
Russian (ru)
Other versions
RU2669920C2 (en
Inventor
Се-Йеон КАНГ
БО-Рам ЧАЕ
Еун-Дзин СУНГ
Дзонг-Хиун ЛИ
Сех-Хион СОНГ
Се-Ил СОН
Хонг-Воо ЛИ
Original Assignee
Дае Вон Фармасьютикал Ко.,Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дае Вон Фармасьютикал Ко.,Лтд. filed Critical Дае Вон Фармасьютикал Ко.,Лтд.
Publication of RU2016118775A publication Critical patent/RU2016118775A/en
Application granted granted Critical
Publication of RU2669920C2 publication Critical patent/RU2669920C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (4)

1. Фармацевтическая композиция, содержащая пелубипрофен и полимер контролируемого высвобождения, где полимером контролируемого высвобождения является водонерастворимый полимер.1. A pharmaceutical composition comprising pelubiprofen and a controlled release polymer, wherein the controlled release polymer is a water-insoluble polymer. 2. Фармацевтическая композиция по п. 1, отличающаяся тем, что композиция растворяется менее чем на 30% в гастроинтестинальной области (растворяющая жидкость с pH 1,2) в течении 2 часов.2. The pharmaceutical composition according to claim 1, characterized in that the composition is dissolved by less than 30% in the gastrointestinal region (dissolving liquid with a pH of 1.2) within 2 hours. 3. Фармацевтическая композиция по п. 2, отличающаяся тем, что композиция растворяется более чем на 50% в области тонкого кишечника(растворяющая жидкость с pH 6,8) в течение 2 часов.3. The pharmaceutical composition according to claim 2, characterized in that the composition is dissolved by more than 50% in the small intestine (dissolving liquid with a pH of 6.8) within 2 hours. 4. Фармацевтическая композиция по п. 2 или 3, отличающаяся тем, что водонерастворимый полимер выбран из группы, состоящей из карбомера, производных целлюлозы, выбраных из карбоксиметилцеллюлозы кальция, целлюлозы ацетата фталата, метилцеллюлозы, гидроксипропил метилцеллюлозы фталата, воска выбранного из микрокристаллического воска, белого воска, карнаубского воска, спермацета и эмульгирующего воска, метакрилатного сополимера, этилцеллюлозы, поливинилацетата, Коллидона SR и их смесей.4. The pharmaceutical composition according to claim 2 or 3, characterized in that the water-insoluble polymer is selected from the group consisting of carbomer, cellulose derivatives selected from calcium carboxymethyl cellulose, cellulose acetate phthalate, methyl cellulose, hydroxypropyl methyl cellulose phthalate, wax selected from microcrystalline wax, white wax, carnauba wax, spermaceti and emulsifying wax, methacrylate copolymer, ethyl cellulose, polyvinyl acetate, Collidon SR and mixtures thereof.
RU2016118775A 2013-10-17 2014-10-14 Controlled release pharmaceutical composition based on propionic acid RU2669920C2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020130124001A KR101561345B1 (en) 2013-10-17 2013-10-17 Controlled-release pharmaceutical composition of propionic acid derivatives
KR10-2013-0124001 2013-10-17
PCT/KR2014/009634 WO2015056956A1 (en) 2013-10-17 2014-10-14 Controlled release pharmaceutical composition based on propionic acid

Publications (2)

Publication Number Publication Date
RU2016118775A true RU2016118775A (en) 2017-11-22
RU2669920C2 RU2669920C2 (en) 2018-10-17

Family

ID=52828338

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016118775A RU2669920C2 (en) 2013-10-17 2014-10-14 Controlled release pharmaceutical composition based on propionic acid

Country Status (4)

Country Link
KR (1) KR101561345B1 (en)
CN (1) CN105705166B (en)
RU (1) RU2669920C2 (en)
WO (1) WO2015056956A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102462607B1 (en) * 2020-11-11 2022-11-03 대원제약주식회사 Pharmaceutical composition with improved stability comprising novel salt of pelubiprofen as an active ingredient

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050095299A1 (en) * 2003-10-30 2005-05-05 Wynn David W. Controlled release analgesic suspensions
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
WO2007129169A2 (en) * 2006-05-04 2007-11-15 Pfizer Limited Cox- ii inhibitors for improving reproductive success in a female animal
WO2008008434A1 (en) * 2006-07-11 2008-01-17 Mutual Pharmaceutical Company, Inc. Controlled-release formulations
CN101500542A (en) * 2006-07-11 2009-08-05 共有药物有限公司 Controlled release formulations
KR100922519B1 (en) * 2008-11-12 2009-10-20 대원제약주식회사 Pharmaceutical preparations for oral administration with improved dissolution rate and stability containing felubiprofen
KR20100130882A (en) * 2009-06-04 2010-12-14 삼아제약 주식회사 Sustained release nonsteroidal anti-inflammatory composition and preparation method thereof
EP2605650A4 (en) * 2010-08-18 2014-05-21 Del Mar Pharmaceuticals COMPOSITIONS AND METHODS FOR IMPROVING PROFIT TREATMENT OF CHEMICAL COMPOUNDS IN ADMINISTRATION WAY SUB-OPTIMAL INCLUDING hexitols SUBSTITUTED AS DIANHYDROGALACTITOL COMPOSITIONS AND DIACÉTYLDIANHYDROGALACTITOL AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF CHEMICAL COMPOUNDS IN ADMINISTRATION WAY SUB-OPTIMAL AS DIANHYDROGALACTITOL AND DIACÉTYLDIANHYDROGALACTITOL

Also Published As

Publication number Publication date
CN105705166B (en) 2019-08-09
CN105705166A (en) 2016-06-22
KR101561345B1 (en) 2015-10-16
RU2669920C2 (en) 2018-10-17
KR20150044670A (en) 2015-04-27
WO2015056956A1 (en) 2015-04-23

Similar Documents

Publication Publication Date Title
RU2014101227A (en) COATING COMPOSITION SUITABLE FOR PHARMACEUTICAL OR NUTRICEUTIC MEDICINAL FORMS
ES2586057T3 (en) Sustained release tablet comprising pregabalin through a two phase release control system
NZ708272A (en) Pharmaceutical composition with improved bioavailability
EA201990223A1 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION WITH CONTROLLED DISSOLUTION SPEED CONTAINING Slow-Release PELLETS CONTAINING TAMSULOSINE HYDROCHLORIDE
HRP20171512T1 (en) BETULINE DERIVATIVES
RU2014138378A (en) NANOCRYSTALLINE CELLULOSE (NCC) IN TAPE SEWING COMPOSITIONS (SC)
MX368859B (en) Solid dosage formulations of an orexin receptor antagonist.
RU2012100709A (en) NEW PHARMACEUTICAL COMPOSITIONS CONTAINING PREGABALIN
JP2016516835A5 (en)
BR112017019920A2 (en) The solid tablet containing colorant
CA2797812A1 (en) Enteric tablet
RU2016143195A (en) APPLICATION OF LACTOBACILIUS RHAMNOSUS FOR STIMULATING THE RESTORATION OF INTESTINAL INTESTINAL MICROBIOTA AFTER DYSBACTERIOSIS
RU2016150178A (en) ALLISARTAN ISOPROXYL SOLID DISPERSION AND PHARMACEUTICAL COMPOSITION
RU2015140119A (en) Enteric Coated Tablet
RU2016118775A (en) Prionic Acid Controlled Release Pharmaceutical Composition
EA201591787A1 (en) TABLETS OWNERS
RU2012110454A (en) METHOD FOR PRODUCING MICROCapsules OF MEDICINES OF THE CEPHALOSPORIN GROUP IN INTERFERON
RU2013130309A (en) SOLID MOLECULAR DISPERSION
RU2012151315A (en) Enteric TABLET
RU2017114677A (en) ORAL DECAYING SOLID PHARMACEUTICAL DOSING UNIT CONTAINING CONTROL GENERAL ACTIVITY SUBSTANCE
RU2017121505A (en) COMPOSITION OF CEFPODOXYM PROXETYL WITH PROLONGED RELEASE
JP2009519313A5 (en)
EA201791523A1 (en) ORAL PHARMACEUTICAL COMPOSITION CONTAINING GRANULES WITH SLOW-DOWNSHEATING, CONTAINING TAMSULOSINE HYDROCHLORIDE
RU2010154205A (en) SOLID MEDICINAL FORM OF MEMANTINE PREPARATIONS AND ITS SALTS
Anwar et al. THE INFLUENCE OF HPMC TO CO-PROCESSED CHITOSAN-SODIUM STARCH GLYCOLAT AS MATRIX TABLET FLOTING FORMULATION